Procter & Gamble Health Limited (PGHL.NS) Bundle
From its founding as Merck Limited in 1967 to the strategic rebrand to Procter & Gamble Health Limited in May 2019, PGHL - headquartered in Mumbai - has carved out a decisive role in India's consumer health space with trusted brands like Neurobion, Evion and Polybion; in FY 2024-25 the company reported revenue of ₹12.84 billion (up 5.80% year-on-year) and net income of ₹3.07 billion (up 24.98%), while its shares traded at ₹5,577.50 on the NSE with a market capitalization of ₹92.61 billion as of December 12, 2025 - a performance underpinned by diversified OTC, vitamin and supplement sales, economies of scale, export channels, R&D-driven product innovation, a centralized Mumbai-led management and multi-channel marketing that includes digital and healthcare-professional partnerships, supported by dividend returns (an interim dividend of ₹80 per share in 2024-25) and positioning PGHL to compete in a market projected to grow at a CAGR of 8.8% to 2030 while pursuing sustainability, ethical sourcing and broader e-commerce and digital initiatives.
Procter & Gamble Health Limited (PGHL.NS): Intro
Procter & Gamble Health Limited (PGHL.NS) traces its origins to 1967 when it was established as Merck Limited, a subsidiary of the German Merck Group. Headquartered in Mumbai, India, the company operates across pharmaceutical and consumer health sectors, manufacturing and marketing over-the-counter (OTC) medicines, vitamins, minerals, and supplements. In May 2019 the company rebranded from Merck Limited to Procter & Gamble Health Limited to align with its parent company's global identity and strategic focus on consumer health.- Founded: 1967 (as Merck Limited)
- Rebranded: May 2019 to Procter & Gamble Health Limited
- Headquarters: Mumbai, India
- Primary sectors: Pharmaceutical, Consumer Health (OTC, vitamins, supplements)
- Vitamins & supplements: Neurobion, Polybion, Evion, Seven Seas
- Prescription & OTC medicines: Nasivion, Livogen
- Dermatology & personal care: Cosome
- Distribution channels: Retail pharmacies, modern trade, e-commerce, institutional sales
| Fiscal Year | Revenue (₹ billion) | YoY Revenue Growth | Net Income (₹ billion) | YoY Net Income Growth |
|---|---|---|---|---|
| 2023-24 | 11.51 | - | 2.46 | - |
| 2024-25 | 12.84 | 5.80% | 3.07 | 24.98% |
- Parent: Procter & Gamble (post-rebrand alignment; operates as part of P&G's consumer health strategy in India)
- Listed entity: PGHL.NS (traded on Indian exchanges)
- Shareholder mix: institutional investors, retail shareholders, promoter/parent holdings (standard public company structure)
- Mission: Deliver trusted health and wellbeing products through science-backed formulations and wide accessibility.
- Priorities: Strengthen OTC and supplement portfolios, expand modern trade and e-commerce reach, invest in brand-building and R&D for consumer health.
- Product development: Formulation and clinical/scientific validation for vitamins, supplements and OTC medicines.
- Manufacturing: In-house and contract manufacturing for domestic supply and regulatory compliance.
- Marketing & distribution: Multi-channel promotion (mass media, digital, professional outreach) and distribution via pharmacies, supermarkets, institutional tenders, and online marketplaces.
- Revenue drivers: Branded product sales (OTC, vitamins & supplements), prescription medicines, licensing and co-marketing partnerships.
- Margin profile: Higher gross margins from branded vitamins/supplements; profitability boosted by brand premium and scale-reflected in a 24.98% YoY net income increase in FY 2024-25.
Procter & Gamble Health Limited (PGHL.NS): History
Procter & Gamble Health Limited (PGHL.NS) traces its origins to P&G's longstanding presence in India and the global health-care and consumer health consolidation strategy. Incorporated as a separate public entity to focus on consumer health brands, PGHL operates under the strategic oversight of Procter & Gamble Overseas India B.V., a subsidiary of The Procter & Gamble Company.- Parent company: Procter & Gamble Company (via Procter & Gamble Overseas India B.V.).
- Stock listing: National Stock Exchange of India - ticker PGHL.
- Investor base: institutional investors, retail investors and employee shareholders.
| Metric | Value / Note |
|---|---|
| Listed Ticker | PGHL (NSE) |
| Share Price (12-Dec-2025) | ₹5,577.50 |
| Market Capitalization (12-Dec-2025) | ₹92.61 billion |
| Dividend (FY 2024-25) | Interim dividend: ₹80 per equity share |
| Major Shareholder | Procter & Gamble Overseas India B.V. (group parent) |
- Revenue drivers: branded OTC medicines, health supplements, consumer wellness products, and licensing/royalty arrangements with group affiliates.
- Profitability levers: brand premium pricing, scale in procurement, and marketing efficiency supported by P&G.
- Capital returns: declared interim dividends (₹80/share for FY24-25) and cash flow allocation guided by parent oversight.
Procter & Gamble Health Limited (PGHL.NS): Ownership Structure
Procter & Gamble Health Limited (PGHL.NS) operates as the health-and-wellness arm connected to the global Procter & Gamble platform. Its mission and corporate values align with P&G's legacy while focusing on consumer health products, innovation, sustainability and community impact.- Mission: Improve quality of life for consumers by providing high‑quality health and wellness products that are safe, effective and accessible.
- Innovation: Invests in product development and formulation improvements to meet evolving consumer needs.
- Sustainability: Commits to eco-friendly packaging, reduced waste and ethical sourcing to minimize environmental footprint.
- Integrity & Transparency: Upholds ethical business practices, clear labeling and compliance with regulatory standards.
- Inclusivity & Diversity: Promotes diverse hiring, inclusive workplace practices and varied perspectives to drive innovation.
- Corporate Social Responsibility: Engages in community health programs, public education and targeted giving to support well‑being.
- Product portfolio: OTC medicines, vitamins & supplements, consumer health devices and personal health consumables sold through retail, pharmacy chains and e‑commerce.
- Channels: Modern trade, pharmacy networks, online marketplaces and institutional sales (clinics, hospitals, wellness programs).
- Revenue model: Direct product sales, private‑label manufacturing partnerships, licensing of formulations/brands and occasional strategic co‑promotions.
- Margin drivers: Brand premium, scale economies in manufacturing, cost optimization in sourcing and higher‑margin specialty health products.
| Holder | Role | Notes / Representative Figures |
|---|---|---|
| Procter & Gamble Co. (Parent) | Major strategic shareholder & technology/resource partner | Provides global R&D, brand IP and supply‑chain integration; parent company reported net sales ≈ $82.0B (FY2023) and ~101,000 employees globally |
| Institutional Investors | Mutual funds, pension funds, asset managers | Hold significant public float; provide liquidity and governance oversight via board representation |
| Retail/Public Shareholders | Small investors and retail traders | Participate in market trading on NSE; contribute to free float and secondary market pricing |
| Promoters / Management | Executive leadership and local management team | Operates day‑to‑day business, implements sustainability and CSR programs |
| Metric | Figure / Comment |
|---|---|
| Parent company net sales (FY2023) | $82.0 billion |
| Parent R&D spend (annual) | ≈ $2.1 billion |
| Global workforce (Parent) | ≈ 101,000 employees |
| Typical channel margin split | Retail/Pharmacy (low‑mid margins), Specialty products & direct channels (higher margins) |
- Packaging goals: progressive targets to reduce virgin plastic use and increase recyclable content across product lines.
- Ethical sourcing: supplier code of conduct and third‑party audits to ensure labor and materials standards.
- Community programs: targeted health education and access initiatives in partnership with NGOs and public health bodies.
Procter & Gamble Health Limited (PGHL.NS): Mission and Values
Procter & Gamble Health Limited (PGHL.NS) is the India-listed health-care and personal wellness arm operating under the Procter & Gamble global umbrella. The company focuses on consumer health products spanning nutritionals, OTC remedies, personal care formulations, and medical consumables. Its stated mission aligns with improving everyday health and well-being through science-backed products, accessible distribution, and sustained consumer trust. For the full mission and vision articulation, see: Mission Statement, Vision, & Core Values (2026) of Procter & Gamble Health Limited. How It Works Procter & Gamble Health Limited (PGHL.NS) operates with a centralized decision-making model headquartered in Mumbai. Core capabilities and activities include product development, manufacturing oversight, supply chain management, regulatory compliance, and multi-channel marketing. Key operational highlights:- Centralized management: Major strategic, portfolio, pricing, and regulatory decisions are taken at the Mumbai headquarters to ensure alignment with both local market needs and global P&G standards.
- Dedicated R&D: A focused R&D team works on formulation development, clinical validation, stability testing, and packaging innovation to maintain efficacy and safety.
- Robust supply chain: Integrated sourcing -> manufacturing -> distribution network supports both domestic India coverage and selective exports to regional markets.
- Multi-channel marketing: Combination of digital platforms (e‑commerce, social, D2C), traditional retail partnerships, and pharmacy/chemist networks to reach diversified consumer segments.
- Healthcare professional engagement: Formal KOL (key opinion leader) programs, medical liaison activities, and scientific advisory boards strengthen product credibility and acceptance among prescribers and pharmacists.
- Employee development: Structured training, GMP and regulatory upskilling, and leadership development programs to sustain operational excellence and compliance.
| Metric | Value | Notes / Timeframe |
|---|---|---|
| Headquarters | Mumbai, India | Centralized corporate & regulatory functions |
| Employees (India) | ~1,200 | Corporate, R&D, manufacturing & commercial (approx. 2024) |
| R&D staff | ~150 | Formulation scientists, clinical specialists, regulatory scientists |
| Manufacturing footprint | 3 owned/contract sites + multiple CDMOs | Domestic plants for OTC, nutritionals and personal care |
| Annual R&D spend | ~2-3% of revenue | Typical consumer-health benchmarking (company-aligned) |
| Distribution reach | ~200,000 retail outlets | Includes modern trade, pharmacies, rural distributors |
| Digital sales share | ~15-25% | E‑commerce and D2C combined (growing YoY) |
| Market cap (listed entity) | INR ~30,000-50,000 crore | Indicative range (varies with public markets) |
| Annual revenue (PGHL India operations) | INR ~3,000-6,000 crore | Indicative range reflecting consumer-health product lines |
- Product sales: Core revenue from OTC medicines, nutritionals, vitamins, consumer health and personal care products sold through pharmacies, retailers and e‑commerce.
- Channel mix premiums: Higher-margin direct-to-consumer (D2C) and e‑commerce sales augment traditional retail margins.
- Private label & contract manufacturing: Revenue from contract manufacturing for third parties and selective private-label arrangements.
- Geographic exports: Sales to neighboring markets and selective global channels augment domestic revenue.
- Service & licensing: Income from licensing proprietary formulations, co-marketing agreements, and professional education programs.
- Regulatory compliance: Adherence to CDSCO (India), FSSAI (for nutritionals), and global standards where applicable.
- Quality systems: GMP, stability testing, batch-release protocols and regular third-party audits.
- Clinical evidence: Targeted clinical/consumer studies to substantiate claims and through-the-line materials for healthcare professionals.
- Training programs: Regulatory, GMP, sales effectiveness, and consumer safety training across operations.
- Leadership development: Talent pipelines to align with parent-group governance and local market needs.
- Technology investments: ERP, supply-chain visibility tools, and e‑commerce analytics to drive operational efficiencies.
Procter & Gamble Health Limited (PGHL.NS): How It Works
Procter & Gamble Health Limited (PGHL.NS) operates as a consumer health and wellness company focused on over-the-counter (OTC) medicines, vitamins, minerals and supplements (VMS), and consumer healthcare products sold under multiple brand names in India and exported to international markets. The company combines manufacturing scale, distribution reach and R&D-driven product innovation to convert formulation pipelines into recurring retail sales, institutional contracts and export shipments.- Core product categories: OTC medicines (cold & flu, analgesics, antacids), vitamins & dietary supplements, health consumables (topicals, digestive aids) and adjacent wellness products.
- Channels to market: modern retail, pharmacy chains, e-commerce marketplaces, institutional sales (clinics, hospitals) and exports to neighboring and global markets.
- R&D and innovation focus: formulation improvements, dosage forms, sustained-release and consumer-preferred delivery formats to support premium pricing and category growth.
- Manufacturing and product sales - primary revenue from selling branded OTC, VMS and wellness products through domestic retail and export channels.
- Brand licensing and partnerships - income from co-branded products, contract manufacturing for third parties, and collaboration revenue with healthcare distributors and local pharma partners.
- Geographic mix - a revenue base comprised of domestic retail sales supplemented by exports that leverage scale and strengthen utilization of manufacturing capacity.
- Cost and margin drivers - economies of scale, optimized procurement of APIs and packaging, and manufacturing consolidation lower unit costs and improve gross margins.
- Pricing & product mix - premium SKUs and differentiated formulations command higher ASPs (average selling prices), boosting top-line growth and operating margins.
| Metric | Typical Range / Example |
|---|---|
| Revenue streams (by contribution) | OTC medicines ~40-55%, VMS ~25-40%, other wellness & exports ~10-25% |
| Gross margin | ~45-60% (driven by branded products and scale) |
| EBIT margin | ~12-20% (depends on marketing investment and export mix) |
| Export share of sales | ~15-40% (growing with international channel expansion) |
| R&D and advertising spend | R&D ~1-3% of sales; marketing/advertising ~8-15% of sales |
| Unit economics | Lower per-unit COGS with higher volumes; breakeven improves after fixed cost absorption by export-led capacity utilization |
- Product lifecycle: in-house R&D → formulation → scale manufacturing → go-to-market via multiple channels → lifecycle management through line extensions and new SKUs.
- Distribution optimization: national distributor network plus direct-to-retailer programs and e-commerce partnerships to increase assortment and shelf share.
- Promotional & pricing strategy: trade discounts, trade marketing, periodic promotional packs and premium SKUs to balance volume growth with margin expansion.
- Partnerships: co-promotion agreements with pharmacies, private-label/contract-manufacture deals and strategic alliances with regional distributors to enter adjacent markets faster.
- Scale benefits - higher utilization of manufacturing plants reduces fixed cost per unit and improves gross margins.
- Portfolio mix - shifting sales toward higher-margin supplements or premium OTC SKUs raises average margins.
- Channel mix - digital and modern-retail sales typically show higher ASP and lower trade discounts than traditional trade, improving net realized prices.
- Innovation cadence - frequent product launches and reformulations sustain consumer interest and justify price premiums.
| KPI | Target / Observed Range |
|---|---|
| Monthly sell-through growth | 5-12% YoY for successful SKUs |
| Inventory turns | 6-10 turns per year (improving with distribution efficiency) |
| New product contribution | 10-20% of annual incremental revenue |
| Export revenue growth rate | 15-30% YoY (when expanding into new markets) |
- External collaborations - partnerships with local healthcare firms and distributors accelerate market entry and diversify revenue streams.
- Contract manufacturing - capacity monetization via third-party manufacturing agreements generates incremental margin-accretive revenue.
- Regulatory compliance & quality systems - robust QA/QC and regulatory approvals enable exports and higher-value institutional contracts.
Procter & Gamble Health Limited (PGHL.NS): How It Makes Money
Procter & Gamble Health Limited (PGHL.NS) monetizes its presence in India's consumer healthcare and adjacent wellness categories through a combination of branded product sales, licensing, partnerships, and increasingly direct-to-consumer channels. The business model leverages P&G's global R&D and brand equity while tailoring portfolios and go-to-market execution for Indian demographics and retail dynamics.- Primary revenue streams: over-the-counter (OTC) branded healthcare products, consumer health supplements, licensing and co-branded consumer health products, and private label/manufacturer contracts.
- Distribution channels: traditional trade (pharmacies, kirana), modern trade, e‑commerce marketplaces, and direct-to-consumer (DTC) platforms.
- Growth enablers: brand extensions, new product introductions, marketing & digital investment, and trade partnerships with pharmacy chains and online retailers.
| Revenue Stream | Approx. Contribution (estimate) | Driver |
|---|---|---|
| Branded OTC & Consumer Health Products | 55-65% | Retail pharmacy and modern trade penetration, brand loyalty |
| Supplements & Wellness | 15-20% | Rising health awareness, preventive care trends |
| Licensing & Co‑branding | 5-10% | Partnerships leveraging P&G IP |
| E‑commerce & DTC Sales | 10-15% | Digital marketing, marketplace presence, subscription models |
| Institutional / B2B Contracts | 3-7% | Healthcare institutions, corporate wellness programs |
- Market growth: India's consumer healthcare market is projected to grow at a compound annual growth rate (CAGR) of 8.8% through 2030, supporting volume and value expansion for established players like PGHL.
- Competitive landscape: PGHL faces competition from domestic firms (large Indian pharma and FMCG players) and international consumer health companies active in India, requiring continuous innovation and price/packaging strategies.
- Portfolio expansion: management focus is on new SKUs in high-growth segments (digestive health, immunity, women's health) and premiumization of established brands to capture higher margins.
- Digital & e‑commerce investments: accelerating spend on digital transformation, CRM, e‑commerce platform optimize, and analytics to grow online share and lower customer acquisition costs.
- Sustainability & governance: PGHL is aligning product sourcing, packaging reduction, and ethical practices with global P&G sustainability goals to meet regulatory and consumer expectations.
- Growth outlook drivers: demographic tailwinds (urbanization, rising middle class), increased healthcare spending per capita, and shifting consumer preferences toward preventive & self-care products support optimistic medium-term growth prospects.
Procter & Gamble Health Limited (PGHL.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.